Plasma ADMA associates with all-cause mortality in renal transplant recipients by Anne-Roos S. Frenay et al.
1 3
DOI 10.1007/s00726-015-2023-0
Amino Acids (2015) 47:1941–1949
ORIGINAL ARTICLE
Plasma ADMA associates with all‑cause mortality in renal 
transplant recipients
Anne‑Roos S. Frenay1 · Else van den Berg2 · Martin H. de Borst2 · 
Bibiana Beckmann3 · Dimitrios Tsikas3 · Martin Feelisch4 · Gerjan Navis2 · 
Stephan J. L. Bakker2 · Harry van Goor1 
Received: 3 April 2015 / Accepted: 1 June 2015 / Published online: 16 June 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
(7 %) patients developed graft failure. ADMA was associ-
ated with increased all-cause mortality [HR 1.52 (95 % CI 
1.26–1.83] per SD increase, P < 0.001], whereby associa-
tions remained upon adjustment for confounders. ADMA 
was associated with graft failure [HR 1.41 (1.08–1.83) per 
SD increase, P = 0.01]; however, upon addition of eGFR 
significance was lost. High levels of plasma ADMA are 
associated with increased mortality in RTR. Our findings 
connect disturbed NO metabolism with patient survival 
after kidney transplantation.
Keywords Asymmetric dimethylarginine · Kidney · 
Survival · Transplantation
Abbreviations
ADMA  Asymmetrical dimethylarginine
BMI  Body mass index
BSA  Body surface area
CKD  Chronic kidney disease
DBP  Diastolic blood pressure
DDAH  Dimethylarginine dimethylaminohydrolase
Egfr  Estimated glomerular filtration rate
FGF-23  Fibroblast growth factor 23
HbA1c  Glycated hemoglobin
hsCRP  High-sensitive C-reactive protein
HDL  High-density lipoprotein
HLA  Human leukocyte antigen
HR  Hazard risk
IQR  Interquartile range
KTx  Kidney transplantation
LDL  Low-density lipoprotein
eNOS  Endothelial nitric oxide synthase
NT-pro-BNP  N-terminal pro-brain natriuretic peptide
PTH  Parathyroid hormone
QC  Quality control
Abstract Asymmetric dimethylarginine (ADMA) is 
a key endogenous inhibitor of endothelial NO synthase 
that affects endothelial function, blood pressure and vas-
cular remodeling. Increased plasma levels of ADMA are 
associated with worse outcome from cardiovascular dis-
ease. Due to endothelial dysfunction before and after kid-
ney transplantation, renal transplant recipients (RTR) are 
at high risk for the alleged deleterious effects of ADMA. 
We investigated the associations of ADMA levels with all-
cause mortality and graft failure in RTR. Plasma ADMA 
levels were determined in 686 stable outpatient RTR 
(57 % male, 53 ± 13 years), with a functioning graft for 
≥1 year. Determinants of ADMA were evaluated with mul-
tivariate linear regression models. Associations between 
ADMA and mortality were assessed using multivariable 
Cox regression analyses. The strongest associations with 
plasma ADMA in the multivariable analyses were male 
gender, donor age, parathyroid hormone, NT-pro-BNP 
and use of calcium supplements. During a median follow-
up of 3.1 [2.7–3.9] years, 79 (12 %) patients died and 45 
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RTR  Renal transplant recipients
SBP  Systolic blood pressure
Introduction
The increased incidence of chronic kidney disease 
(CKD) over the last decades is related to the aging 
population and to lifestyle-related diseases, e.g., hyper-
tension, atherosclerosis and diabetes. For patients pro-
gressing to end-stage renal disease, renal replacement 
therapy is the final treatment option. When compared 
to the general population, patients receiving renal 
replacement therapy are at increased risk of infections, 
malignancies and cardiovascular events (Vogelzang 
et al. 2015). In renal transplant recipients (RTR), one 
of the main pathophysiological processes that contrib-
ute to premature cardiovascular disease is endothelial 
dysfunction. Different processes including decreased 
expression of glomerular endothelial nitric oxide syn-
thase (eNOS) expression after renal transplantation 
(Albrecht et al. 2002) are thought to play a role in 
these adverse events. The subsequent reduction in NO 
release may cause vascular damage through changes in 
the renal hemodynamics (Nakayama et al. 2009) and 
enhanced endothelial adhesion of leukocytes and plate-
lets (Huang et al. 1995).
Asymmetric dimethylarginine (ADMA) is an endog-
enous inhibitor of endothelial nitric oxide (NO) synthase 
and thereby considered an adverse mediator of endothe-
lial function (Cooke 2000; Yilmaz et al. 2006). ADMA 
is associated with cardiovascular risk factors in patients 
with hypertension (Surdacki et al. 1999), diabetes (Can 
et al. 2011) and hyperlipidemia (Boger et al. 1998). This 
is further evidenced by increased plasma levels of ADMA 
in patients with CKD, which are linked to both the devel-
opment and the progression of CKD (Ravani et al. 2005; 
Fliser et al. 2005; Hanai et al. 2009). In pre-dialysis patients 
with CKD, circulating levels of ADMA are an independent 
risk factor for left ventricular hypertrophy with predictive 
value for cardiovascular events (Shi et al. 2010). Interest-
ingly, a recent study in patients with CKD demonstrated a 
link between levels of ADMA and fibroblast growth fac-
tor-23 (FGF-23), which by itself is also linked to markers of 
endothelial cell injury (Malyszko et al. 2014), in the devel-
opment of endothelial dysfunction (Yilmaz et al. 2010). 
Furthermore, a recent study in CKD patients suggested that 
the association between ADMA level and CKD progression 
is modified by FGF23 (Tripepi et al. 2015). Whether this 
effect modification also occurs in renal transplant recipients 
for graft and patient survival, or whether the association 
between ADMA and these outcomes is mediated by FGF-
23 is unknown.
Based on the characteristics of ADMA, especially those 
related to endothelial dysfunction, we hypothesized that 
ADMA is associated with graft failure and mortality after 
kidney transplantation. We investigated this in a cohort of 
686 renal transplant recipients with long-term follow-up.
Methods
Study design and population
From November 2008 till June 2011, all stable RTR 
(≥18 years, n = 817) with a functioning graft for over 
1 year that visited the outpatient clinic of the University 
Medical Center Groningen (UMCG), the Netherlands were 
invited to participate. After giving written informed con-
sent, a total of 707 (87 %) RTR participated in the present 
study. Plasma ADMA was measured in samples of 686 
RTR (97 %). Further details of the study population have 
been published previously (van den Berg et al. 2012a, b, 
2014). The study protocol was approved by the Review 
Board of the UMCG (METc 2008/186) and was in adher-
ence to the Declaration of Helsinki.
Outcome parameters
The primary outcome measures of this study were death-
censored graft failure (defined as restart of dialysis or re-
transplantation) and all-cause mortality. Outcome measures 
were recorded until the end of May 2013, with no partici-
pants lost to follow-up.
Clinical parameters
As described previously (van den Berg et al. 2014), all par-
ticipants were instructed to collect 24-h urine sample at the 
day prior to their visit to the outpatient clinic. First, blood 
pressure and heart rate were measured using a semi-auto-
matic device (Dinamap® 1846, Critikon, Tampa, FL, USA) 
every minute for the duration of 15 min, following a strict 
protocol (van den Berg et al. 2012a, b). An average of the 
last three values was taken as a final value. Body weight 
and height were measured and body mass index (BMI) 
was calculated as weight divided by height square (kg/
m2), body surface area was calculated using the universally 
adopted formula of DuBois & DuBois (Dubois and Dubois 
1989). In the morning after an overnight fasting period, 
blood was drawn and subsequently venous blood gas analy-
ses were performed photometrically. Electrolytes, phos-
phate, albumin, urea and creatinine in plasma and urine 
were measured using routine laboratory methods, which 
was also the case for serum cholesterol, HbA1c and hsCRP. 
Renal function was assessed by calculating the estimated 
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glomerular filtration rate (eGFR) using the CKD Epide-
miology Collaboration (CKD-EPI) equation (Levey Levey 
et al. 2009). Serum calcium was corrected for hypoalbu-
minemia (<40 g/L) using the following formula: corrected 
calcium = serum calcium (mmol/L) + 0.02 × [40 − serum 
albumin (g/L)]. Intact FGF-23 was measured using a com-
mercially available ELISA kit (Kainos Laboratories, Inc., 
Tokyo, Japan) (Baia et al. 2014). Information on partici-
pants’ health status, medical history and medication use 
was extracted from patient records. Relevant transplant 
information was extracted from the UMCG renal transplant 
database. Smoking behavior was categorized to current, 
former or never smoked, using a self-report questionnaire.
Plasma ADMA
Free ADMA was measured by a previously described fully 
validated GC–MS/MS method (Tsikas et al. 2003). The 
analyses were performed on a ThermoQuest TSQ 7000 
mass spectrometer (Finnigan MAT, San Jose, CA, USA). 
ADMA was quantified by selected-reaction monitoring 
(SRM) of the transitions mlz 634 → mlz 378 for endog-
enous ADMA, whereas for the internal standard mlz 
637 → mlz 378 was used. The dwell time was 100 ms for 
each analyte and each transition. The basal plasma concen-
tration of the QC samples was 380 nM for ADMA.
Statistical analysis
Statistical analyses were performed using SPSS 22.0 for 
Windows (SPSS Corp. Chicago, IL, USA) and Graph-
Pad Prism version 5.00 for Windows (GraphPad Soft-
ware, San Diego, CA, USA). Non-normally distributed 
parameters were presented as median [interquartile range 
(IQR)] and normally distributed variables were expressed 
as mean ± standard deviation (SD). A two-sided P 
value <0.05 was considered statistically significant. His-
tograms and probability plots were displayed followed by 
the Kolmogorov–Smirnov test to test the distribution of all 
parameters. When skewed, parameters were normalized 
for analyses by logarithmic transformation [high-sensitive 
C-reactive protein (CRP), triglycerides, albuminuria, FGF-
23, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), 
parathyroid hormone (PTH)]. The study population was 
subdivided into tertiles of ADMA to visualize potential 
associations of plasma ADMA with different parameters 
in RTR. To establish P values for differences in ADMA 
tertiles, an ANOVA was used for normally distributed con-
tinuous data, whereas the Kruskal–Wallis test was used for 
non-normally distributed data and the χ2-test for nominal 
data. To identify the independent determinants of ADMA, 
univariable and multivariable linear regression analyses 
were performed. Multivariable linear regression models 
were constructed using backward selection (Pout > 0.05), 
which included all twenty-one variables that were signifi-
cantly associated with ADMA in the univariable analy-
sis. Tertiles of ADMA were tested for associations with 
all-cause mortality and death-censored graft failure by 
Kaplan–Meier analysis, including the log-rank test. For 
the Cox regression analyses, models were constructed with 
inclusion of the potential confounders of ADMA. These 
are the parameters that significantly associated with plasma 
ADMA in the multivariable analysis. We first performed 
crude Cox regression analyses (model 1) and analyses 
with adjustment for age and gender (model 2). In addition, 
eGFR was added (model 3), and we adjusted for the poten-
tial confounders of ADMA, which were identified in the 
multivariable regression analysis (donor age, serum PTH, 
NT-pro-BNP, use of calcium supplements) (model 4). In 
the final model, we included intact FGF-23, to test whether 
the association of ADMA with all-cause mortality was 
influenced by this parameter (model 5). The same models 
were used to test the association of plasma ADMA with 
graft failure. We explored a potential interaction by FGF-
23 for the association between ADMA and mortality in the 
full Cox regression model by adding the interaction term 
ADMA × FGF-23.
Results
Patient characteristics according to tertiles of plasma 
ADMA
Plasma ADMA was normally distributed and had a mean 
value of 0.61 ± 0.12 µmol/L (Fig. 1). The patient cohort 
of 686 RTR had a mean age of 53.0 ± 12.7 years and 57 % 
were male. Baseline characteristics of the patient cohort 
per tertile of ADMA are displayed in Table 1. Median 
Fig. 1  Histogram of plasma ADMA showing normal distribution 
curve in RTR. Plasma ADMA (0.61 ± 0.12 µmol/L) measured in 686 
renal transplant recipients was normally distributed
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Table 1  Baseline patient characteristics presented as tertiles of plasma ADMA
Renal transplant recipients tertiles of ADMA
Overall (N = 686) Tertile 1 (N = 249) Tertile 2 (N = 213) Tertile 3 (N = 224) P value
ADMA (µmol/L) 0.61 ± 0.12 ≤0.56 0.57–0.65 ≥0.66 <0.001
Demographics
 Age, years 53 ± 13 50 ± 13 54 ± 12 55 ± 13 <0.001
 Male gender 390 (57) 127 (51) 125 (59) 138 (62) 0.05
 Current smoker, n (%) 82 (13) 29 (13) 31 (15) 22 (11) 0.38
 Current diabetes, n (%) 165 (24) 51 (21) 51 (24) 63 (28) 0.15
 BMI, kg/m2 27 ± 5 27 ± 5 27 ± 5 27 ± 5 0.84
 BSA, m2 1.94 ± 0.22 1.94 ± 0.19 1.95 ± 0.22 1.94 ± 0.22 0.72
 Systolic blood pressure, mmHg 136 ± 17 136 ± 16 135 ± 18 138 ± 15 0.26
 Diastolic blood pressure, mmHg 83 ± 11 83 ± 10 82 ± 12 82 ± 11 0.44
 Heart rate, bpm 69 ± 12 69 ± 13 68 ± 12 69 ± 11 0.61
Renal transplantation
 Transplant vintage, years 5.4 [1.9–12.1] 5.2 [2.2–10.8] 5.2 [2.0–11.6] 6.1 [1.6–14.0] 0.51
 Living donor, n (%) 229 (34) 103 (42) 70 (34) 56 (26) 0.001
 Pre-emptive KTx, n (%) 112 (16) 51 (21) 33 (16) 28 (13) 0.06
 HLA mismatches, n 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 0.31
 Age donor, years 43 ± 16 40 ± 16 43 ± 15 45 ± 15 0.009
 Acute rejection, n (%) 181 (26) 65 (26) 54 (26) 62 (28) 0.86
Laboratory measurements
 Hemoglobin, mmol/L 8.2 ± 1.1 8.3 ± 1.0 8.2 ± 1.1 8.1 ± 1.2 0.09
 HbA1C, % 6.0 ± 0.8 5.9 ± 0.8 6.0 ± 0.8 6.0 ± 0.9 0.59
 eGFR, CKD-EPI (ml/min/1.73 m2) 52.2 ± 20.2 57.9 ± 21.4 51.2 ± 18.4 46.9 ± 19.0 <0.001
 Corrected calcium mmol/L 2.34 ± 0.15 2.33 ± 0.15 2.35 ± 0.14 2.35 ± 0.14 0.42
 Phosphate, mmol/L 0.97 ± 0.21 0.94 ± 0.21 0.96 ± 0.21 1.01 ± 0.21 0.002
 Magnesium, mmol/L 0.95 ± 0.12 0.95 ± 0.12 0.95 ± 0.13 0.96 ± 0.12 0.81
 PTH, pmol/L 8.9 [5.9–14.7] 8.1 [5.6–12.0] 8.7 [6.2–15.4] 11.0 [6.5–17.3] 0.001
 Venous pH 7.37 ± 0.04 7.37 ± 0.04 7.37 ± 0.04 7.36 ± 0.04 0.009
 Venous HCO3
−, mmol/L 24.6 ± 3.1 24.8 ± 2.9 24.8 ± 3.2 24.2 ± 3.2 0.07
 hsCRP, mg/L 1.6 [0.7–4.5] 1.6 [0.7–4.6] 1.8 [0.6–5.0] 1.5 [0.8–4.4] 0.91
 Albumin, g/L 43.0 ± 3.0 43.6 ± 2.8 42.9 ± 2.8 42.4 ± 3.2 <0.001
 Alkaline phosphatase, U/L 67 [54–83] 66 [51–79] 67 [56–82] 69 [54–92] 0.12
 FGF-23, pg/mL 61 [43–99] 54 [39–82] 60 [46–93] 75 [53–126] <0.001
 Total cholesterol, mmol/L 5.0 [4.4–5.8] 5.1 [4.4–5.8] 5.0 [4.4–5.8] 5.1 [4.2–5.9] 0.95
 HDL cholesterol, mmol/L 1.3 [1.1–1.6] 1.4 [1.1–1.7] 1.3 [1.1–1.7] 1.3 [1.0–1.5] 0.002
 LDL cholesterol, mmol/L 2.9 [2.3–3.5] 2.9 [2.4–3.5] 2.9 [2.2–3.5] 2.9 [2.3–3.6] 0.83
 Triglycerides, mmol/L 1.68 [1.25–2.30] 1.63 [1.13–2.23] 1.73 [1.29–2.43] 1.69 [1.28–2.3] 0.17
 NT-pro-BNP, ng/L 252 [108–634 150 [76–405] 229 [109–565] 396 [185–1086] <0.001
 Albuminuria, mg/24 h 40 [11–177] 29 [8–154] 28 [10–103] 83 [13–300] 0.001
Medication
 Anti-hypertensives, n (%) 606 (88) 212 (85) 190 (89) 204 (91) 0.12
 Statins, n (%) 361 (53) 132 (53) 105 (50) 361 (53) 0.45
 Calcium supplements, n (%) 147 (21) 46 (19) 46 (22) 55 (25) 0.27
 Vitamin D supplements 168 (25) 63 (25) 44 (21) 61 (27) 0.26
 Vitamin K antagonists 77 (11) 19 (8) 22 (10) 36 (16) 0.01
 Prednisone, mg/d 10 [7.5–10] 10 [7.5–10] 10 [7.5–10] 10 [7.5–10] 0.19
 Calcineurin inhibitors 391 (57) 120 (48) 134 (63) 137 (61) 0.002
 Proliferation inhibitor 572 (83) 222 (89) 171 (80) 179 (80) 0.009
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time between renal transplantation and baseline measure-
ment was 5.4 [1.9–12.0] years. RTR in the highest tertile 
of ADMA were older and more likely to be male compared 
to RTR in the other tertiles, whereas the other demographic 
parameters were similar among ADMA tertiles. With 
regard to transplant characteristics, RTR with the highest 
ADMA levels less often received their kidney from living 
donors, and their donors tended to be older.
Estimated GFR was lower and urinary protein excre-
tion higher in RTR with the highest ADMA. Serum phos-
phate, PTH and levels of NT-pro-BNP were significantly 
increased in RTR in the highest ADMA tertile, whereas 
serum albumin levels, HDL cholesterol and venous pH 
were significantly lower when compared to RTR with the 
lowest ADMA level. RTR with the highest levels of ADMA 
also had the highest levels of intact FGF-23. With regard to 
medication use, RTR with the highest plasma ADMA more 
often used vitamin K antagonist and calcineurin inhibi-
tors when compared to the lowest ADMA tertile, while the 
use of proliferation inhibitors was less. Table 2 provides 
an overview of associations of ADMA levels with differ-
ent parameters in univariable and multivariable regression 
analyses. The strongest associations with plasma ADMA 
in the multivariable analyses were male gender, donor age, 
PTH, NT-pro-BNP and use of calcium supplements. When 
adding NT-pro-BNP to the linear regression analysis with 
backward selection, eGFR lost its significant association 
with ADMA.
ADMA is associated with increased all‑cause mortality 
in RTR, independent of FGF‑23
Of the 686 RTR in our cohort, 79 (12 %) died within a 
median follow-up period of 3.1 [2.7–3.9] years. In the 
highest tertile of ADMA, 44 out of 224 (20 %) died, while 
this was 22 out of 213 (10 %) in the middle tertile and 13 
out of 249 (5 %) in the tertile with the lowest ADMA lev-
els (log-rank test P < 0.001, Fig. 2). In addition, we per-
formed Cox regression analyses with potential confounders 
of plasma ADMA that were identified in the multivari-
able regression analyses (Table 3). The crude Cox regres-
sion analysis (model 1) showed that plasma ADMA is 
associated with increased mortality risk [HR 1.52 (95 % CI 
1.26–1.83), P < 0.001 per SD increase]. After adjusting for 
age and gender [model 2; HR 1.52 (1.22–1.88), P < 0.001], 
for eGFR [model 3; HR 1.43 (1.15–1.78), P = 0.001] 
and other potential confounders in multivariate regression 
analysis [model 4; HR 1.34 (1.07–1.68), P = 0.01], plasma 
ADMA remained significantly associated with increased 
mortality risk in RTR. In the final model, we also added 
FGF-23, however, this did not affect the association of 
plasma ADMA with all-cause mortality [model 5; HR 1.34 
(1.07–1.68), P = 0.01]. We found no significant interaction 
by FGF-23 for the association between ADMA and mortal-
ity (P = 0.23).
ADMA is associated with graft failure in RTR; lost 
significance after adding renal function
In our cohort, 45 (7 %) RTR developed graft failure in a 
median follow-up period of 3.1 [2.7–3.9] years. In the 
highest tertile of ADMA, 19 out of 224 (9 %) developed 
graft failure, while this was 16 out of 213 (8 %) and 10 out 
of 249 (4 %) in the middle and lowest tertile of ADMA, 
respectively (log-rank test P = 0.10). In the crude Cox 
regression analysis, plasma ADMA was significantly asso-
ciated with graft failure [HR 1.41 (1.08–1.83), P = 0.01] 
(Table 4). Upon adjustment for age and gender, plasma 
ADMA remained significantly associated with graft failure 
[HR 1.42 (1.11–1.82), P = 0.01]. However, when adding 
eGFR, the significant association of ADMA with graft fail-
ure was lost (HR 1.26 (0.95–1.68), P = 0.11].
Discussion
Plasma ADMA is associated with increased risk of all-
cause mortality in stable renal transplant recipients. This 
association was solid and independent of various potential 
confounders. These results are in line with the current con-
ception of ADMA as a serious risk factor for cardiovascular 
disease, the primary cause of death in RTR.
ADMA is an endogenous inhibitor of NO synthase that 
has the potential to negatively affect endothelial function, 
Table 1  continued
Renal transplant recipients tertiles of ADMA
Overall (N = 686) Tertile 1 (N = 249) Tertile 2 (N = 213) Tertile 3 (N = 224) P value
 Sirolimus 13 (2) 5 (2) 7 (3) 1 (1) 0.10
Data are presented as mean ± SD, number (percentage) or median (IQR). Statistical analysis was performed using ANOVA, Kruskal–Wallis or 
χ2-test when appropriate. Bold indicates statistical significance (P < 0.05)
ADMA asymmetrical dimethylarginine, BSA body surface area, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HCO3
− 
bicarbonate, HDL high-density lipoprotein, HLA human leukocyte antigen, hsCRP high-sensitivity C-reactive protein, KTx kidney transplanta-
tion, LDL low-density lipoprotein, PTH parathyroid hormone
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blood pressure and vascular remodeling (Leiper 2005) via 
reduction of the production of NO. High levels of ADMA 
are acknowledged as a risk factor for cardiovascular disease 
in CKD patients (Abedini et al. 2010; Lu et al. 2011; Ravani 
et al. 2005) and associate with increased mortality in 
patients undergoing coronary angiography (Meinitzer et al. 
2011). Where others have described ADMA and NT-pro-
BNP as independent risk markers (Duckelmann et al. 
2007), the results of the present study demonstrate a strong 
association between plasma ADMA and NT-pro-BNP 
in RTR. Despite this strong association, our results show 
that ADMA still is an independent risk factor associated 
with mortality in RTR. Since ADMA significantly inhibits 
NOS and reduces NO production in vitro in endothelial 
cells and isolated human blood vessels (Faraci et al. 1995) 
and ADMA administration to healthy rats (Gardiner 
et al. 1993) as well as healthy humans (Kielstein et al. 
2004) induced increased blood pressure, increased renal 
vasculature resistance and decreased cardiac output, one 
might hypothesize that high levels of ADMA can cause left 
ventricular wall stress with increased NT-pro-BNP levels. 
The link between endothelial dysfunction and vascular 
hypertrophy has already been demonstrated in end-stage 
renal disease patients (Zoccali et al. 2002). Furthermore, 
in patients with CKD, plasma ADMA was addressed as 
an independent risk factor for cardiac hypertrophy and 
associated with cardiovascular events (Shi et al. 2010).
We found a borderline significant inverse relationship 
between ADMA and renal function in RTR. This association 
was also demonstrated in CKD patients (Ravani et al. 2005; 
Fliser et al. 2005; Tripepi et al. 2015), whereby ADMA 
predicted the incidence rate of renal events (decrease 
in eGFR of >30 %, dialysis, or kidney transplantation 




St. Beta P value St. Beta P value
Demographics
 Age, years 0.123 <0.001
 Male gender 0.082 0.03 0.133 0.001
 Current smoker −0.011 0.78
 Current diabetes 0.071 0.06
 BMI, kg/m2 −0.046 0.23
 BSA, m2 −0.046 0.23
 SBP, mmHg 0.026 0.50
 DBP, mmHg −0.039 0.31
 Heart rate, bpm 0.006 0.87
Renal transplantation
 Transplant vintage, years 0.04 0.30
 Living donor −0.127 0.001
 Pre-emptive KTx −0.098 0.01
 HLA mismatches −0.022 0.57
 Age donor, years 0.110 0.005 0.094 0.02
 Acute rejection 0.016 0.67
Laboratory measurements
 Hemoglobin, mmol/L −0.082 0.03
 HbA1C, % 0.010 0.80
 eGFR, CKD-EPI (ml/
min/1.73 m2)
−0.209 <0.001
 Corrected calcium mmol/L 0.059 0.13
 Phosphate, mmol/L 0.107 0.005
 Magnesium, mmol/L 0.014 0.72
 PTH, pmol/L 0.119 0.002 0.104 0.01
 Venous pH −0.123 0.002
 Venous HCO3, mmol/L −0.108 0.006
 hsCRP, mg/L −0.016 0.68
 Albumin, g/L −0.160 <0.001
 Alkaline phosphatase, U/L 0.058 0.13
 FGF-23, pg/mL 0.185 <0.001
 Total cholesterol, mmol/L −0.052 0.18
 HDL cholesterol, mmol/L −0.139 <0.001
 LDL cholesterol, mmol/L −0.021 0.58
 Triglycerides, mmol/L 0.036 0.34
 NT-pro-BNP, ng/L 0.271 <0.001 0.265 <0.001
 Albuminuria, mg/24 h 0.115 0.003
Medication
 Anti-hypertensives 0.081 0.03
 Statins 0.032 0.40
 Calcium supplements 0.085 0.03 0.088 0.03
 Vitamin D supplements 0.029 0.44
 Vitamin K antagonists 0.125 0.001
 Prednisone, mg/d 0.055 0.15
Table 2  continued
Plasma ADMA
Univariable Multivariable
St. Beta P value St. Beta P value
 Calcineurin inhibitors 0.092 0.02
 Proliferation inhibitor −0.101 0.008
 Sirolimus −0.065 0.10
Regression coefficients are given as standardized betas, i.e., change 
of cardiovascular parameter in SD, per SD increase of plasma ADMA 
level
P values less than 0.05 are in bold
ADMA asymmetrical dimethylarginine, BMI body mass index, BSA 
body surface area, SBP systolic blood pressure, DBP diastolic blood 
pressure, FGF-23 fibroblast growth factor 23, hsCRP high-sensitive 
C-Reactive Protein, HDL cholesterol high-density lipoprotein, LDL 
low-density lipoprotein, NT-pro-BNP N-terminal pro-Brain Natriu-
retic peptide, PTH parathyroid hormone, HbA1c glycated hemo-
globin, eGFR estimated glomerular filtration rate
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(Tripepi et al. 2015). The association of ADMA with renal 
function decline and renal events might be explained by its 
inhibitory effects on NO production, which in turn leads to 
deteriorated renal function and renal fibrosis (Mihout et al. 
2011). However, in the present study we demonstrated 
that, by the addition of NT-pro-BNP to the multivariate 
model, eGFR lost its significant association with ADMA. 
Apparently, NT-pro-BNP is an even stronger determinant of 
ADMA than renal function. This might be related to the fact 
that they are both involved in cardiovascular dynamics.
Furthermore, others found a link between levels of 
ADMA and graft failure (Abedini et al. 2010). In the present 
study, we confirmed this association; however, significance 
was lost after adjustment for renal function. This can be 
explained by the fact that renal function by itself is a strong 
predictor for graft failure (Hariharan et al. 2002) and might 
also be a consequence of the low number of events in our 
cohort. Thereby, in the present study, the way of classify-
ing graft failure differed from Abedini et al., since we only 
took into account the RTR that returned to dialysis or had to 
undergo re-transplantation, whereas they also included dou-
bling of serum creatinine into this category (Abedini et al. 
2010). Our study is in line with the work of Abedini et al. 
who, in a cohort of renal transplant recipients with slightly 
different patients’ characteristics, also found a significant 
association between ADMA and mortality. However, our 
study adds that ADMA is significantly associated with NT-
pro-BNP, but is independently associated with all-cause mor-
tality. This latter also holds true for ADMA and FGF-23.
A potential shared causal pathway of FGF-23 and 
ADMA in the development of endothelial dysfunction was 
recently proposed (Yilmaz et al. 2010). In line with this, 
FGF-23 was previously reported to modify the association 
between ADMA and renal function loss in CKD patients 
(Tripepi et al. 2015). In the present study, we examined 
whether the association of plasma ADMA with mortal-
ity is mediated by FGF-23, however, from our results we 
conclude that the association between ADMA and all-cause 
mortality is independent of plasma intact FGF-23 in RTR. 
We also found no evidence of interaction by FGF-23 for the 
association between ADMA and mortality in our cohort.
One of the strengths of our study is the large sample 
size of well-defined, stable RTR. Extensive data collec-
tion, including data from 24-h urine samples allowed for 
adjustment for many confounders. Despite this, our study 
is strictly an observational epidemiological study. Causality 
is, therefore, hard to prove. Since little is known about how 
Fig. 2  Kaplan–Meier plot of the association of ADMA with all-cause 
mortality in RTR. Higher plasma levels of ADMA are associated with 
significantly increased all-cause mortality in renal transplant recipi-
ents. Kaplan–Meier curve displayed for all-cause mortality, with log-
rank test P value <0.001
Table 3  Associations of plasma ADMA with all-cause mortality in 
RTR
Model 1: crude, Model 2: adjusted for age, gender, Model 3: as 
model 2, additionally adjusted for Egfr, Model 4: as model 3, addi-
tionally adjusted for donor age, PTH, NT-pro-BNP, use of calcium 
supplements, Model 5: as model 4, additionally adjusted for FGF-23
P values less than 0.05 are in bold
ADMA asymmetric dimethylarginine, CI confidence interval, FGF-23 
fibroblast growth factor 23, HR hazard ratio, NT-pro-BNP N-terminal 
pro-hormone of brain natriuretic peptide, PTH parathyroid hormone, 
SD standard deviation
Plasma ADMA (continuous)
HR (95 % CI) per SD P value
Model 1 1.52 (1.26–1.83) <0.001
Model 2 1.52 (1.22–1.88) <0.001
Model 3 1.43 (1.15–1.78) 0.001
Model 4 1.34 (1.07–1.68) 0.01
Model 5 1.34 (1.07–1.68) 0.01
Table 4  Associations of plasma ADMA with graft failure in RTR
Model 1: crude, Model 2: adjusted for age, gender, Model 3: as 
model 2, additionally adjusted for eGFR, Model 4: as model 3, addi-
tionally adjusted for donor age, PTH, NT-pro-BNP, use of calcium 
supplements, Model 5: as model 4, additionally adjusted for FGF-23
P values less than 0.05 are in bold
ADMA asymmetric dimethylarginine, CI confidence interval, FGF-23 
fibroblast growth factor 23, HR hazard ratio, NT-pro-BNP N-terminal 
pro-hormone of brain natriuretic peptide, PTH parathyroid hormone, 
SD standard deviation
Plasma ADMA (continuous)
HR (95 % CI) per SD P value
Model 1 1.41 (1.08–1.83) 0.01
Model 2 1.42 (1.11–1.82) 0.01
Model 3 1.26 (0.95–1.68) 0.11
Model 4 1.11 (0.81–1.51) 0.52
Model 5 1.10 (0.80–1.49) 0.57
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ADMA affects cardiovascular parameters in this cohort, 
other factors might underlie the observed associations. Fur-
thermore, our study population consisted predominantly of 
Caucasian people, which calls prudence to extrapolation of 
our results to populations of other ethnicities. Furthermore, 
we need to keep in mind that circulating levels of ADMA in 
some cases reflect the intracellular concentrations (Davids 
et al. 2012), however, they are not necessarily in equilib-
rium with each other (Davids and Teerlink 2013).
In conclusion, high levels of plasma ADMA are asso-
ciated with increased mortality in RTR. Since it is not yet 
clear whether ADMA is rather a progression marker of 
disease, a novel risk factor of disease or both, additional 
studies to sort out these issues are warranted. Currently, 
therapies to reduce ADMA levels are being tested for their 
efficacy, as well as to evaluate their therapeutic effect in 
diseases characterized by endothelial dysfunction.
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